These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 18947484

  • 1. [Clinical features of recurrent Kawasaki disease in 20 children].
    Zou LX, Gong FQ.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct; 10(5):617-9. PubMed ID: 18947484
    [Abstract] [Full Text] [Related]

  • 2. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 3. Diagnosis, treatment and outcome of Kawasaki disease in an Australian tertiary setting: a review of three years experience.
    Singh-Grewal D, Wong M, Isaacs D.
    J Paediatr Child Health; 2005 Apr; 41(9-10):495-9. PubMed ID: 16150066
    [Abstract] [Full Text] [Related]

  • 4. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 5. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 6. Characteristics of Kawasaki disease in older children.
    Cai Z, Zuo R, Liu Y.
    Clin Pediatr (Phila); 2011 Oct; 50(10):952-6. PubMed ID: 21628347
    [Abstract] [Full Text] [Related]

  • 7. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 8. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
    [Abstract] [Full Text] [Related]

  • 9. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
    Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R.
    J Paediatr Child Health; 2004 Nov 27; 40(9-10):524-9. PubMed ID: 15367145
    [Abstract] [Full Text] [Related]

  • 10. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 27; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 11. Clinical characteristics of Kawasaki disease according to age at diagnosis.
    Kim SH, Kim KH, Kim DS.
    Indian Pediatr; 2009 Jul 27; 46(7):585-90. PubMed ID: 19638657
    [Abstract] [Full Text] [Related]

  • 12. [Early diagnosis of Kawasaki disease complicated by coronary artery lesions].
    Hu XH, Xu SX, Luan Z.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug 27; 23(8):853-5. PubMed ID: 12919919
    [Abstract] [Full Text] [Related]

  • 13. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug 27; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 14. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
    Pediatrics; 2005 Dec 27; 116(6):e760-6. PubMed ID: 16322132
    [Abstract] [Full Text] [Related]

  • 15. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 27; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 16. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
    Kubota M, Usami I, Yamakawa M, Tomita Y, Haruta T.
    J Paediatr Child Health; 2008 Jun 27; 44(6):359-62. PubMed ID: 18476929
    [Abstract] [Full Text] [Related]

  • 17. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
    J Microbiol Immunol Infect; 2007 Oct 27; 40(5):395-400. PubMed ID: 17932598
    [Abstract] [Full Text] [Related]

  • 18. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
    Kashef S, Safari M, Amin R.
    Kaohsiung J Med Sci; 2005 Sep 27; 21(9):401-4. PubMed ID: 16248123
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug 27; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

  • 20. Clinical features of atypical Kawasaki disease.
    Hsieh YC, Wu MH, Wang JK, Lee PI, Lee CY, Huang LM.
    J Microbiol Immunol Infect; 2002 Mar 27; 35(1):57-60. PubMed ID: 11950122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.